Unravelling the processes permissive of AD aetiology, along with the associated signalling pathways and potential HSPG involvement may allow for improved understanding of how these factors may be targeted to slow down or treat neurodegeneration. This evidence concerns the gene HSPG2 and Alzheimer disease.